Cellectar Biosciences (CLRB)

• Market cap: $13.8M
• 1 day: -5.37%
• 5 days: -4.59%
• 1 month: 6.62%
• 3 months: 15.23%
• 6 months: -85.93%
• Year to date: -7.79%
• 1 year: -91.54%
• 5 years: -98.23%
• 10 years: -99.99%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.

Employees: 20

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

367% more call options, than puts

Call options by funds: $14K | Put options by funds: $3K

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

14% less funds holding

Funds holding: 35 [Q3] → 30 (-5) [Q4]

26.78% less ownership

Funds ownership: 39.13% [Q3] → 12.35% (-26.78%) [Q4]

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

95% less capital invested

Capital invested by funds: $30M [Q3] → $1.53M (-$28.5M) [Q4]

100% less funds holding in top 10

Funds holding in top 10: 2 [Q3] → 0 (-2) [Q4]